{"id":3690,"date":"2021-11-09T17:43:00","date_gmt":"2021-11-10T01:43:00","guid":{"rendered":"https:\/\/allocare.caredx.com\/?p=3690"},"modified":"2022-08-16T14:13:17","modified_gmt":"2022-08-16T21:13:17","slug":"investigational-oral-ckd-anemia-agent-effective-safe","status":"publish","type":"post","link":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2021\/11\/09\/investigational-oral-ckd-anemia-agent-effective-safe\/","title":{"rendered":"Investigational Oral CKD-Anemia Agent Effective, Safe"},"content":{"rendered":"<span class=\"simplefavorite-button has-count loading\" data-postid=\"3690\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>\n<p>&#8220;The investigational hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) daprodustat was safe and as effective as erythropoiesis-stimulating agents (ESAs) for anemia, according to the phase III ASCEND program.<\/p>\n\n\n\n<p>In the first of the two ASCEND trials looking at patients with chronic kidney disease undergoing dialysis, patients treated with oral daprodustat had a mean change in hemoglobin level of 0.28\u00b10.02 g\/dL from baseline to weeks 28 through 52, reported Ajay Singh, MBBS, MBA, of Brigham and Women&#8217;s Hospital in Boston and chair of the ASCEND program&#8217;s Executive Steering Committee, and colleagues.&#8221;<\/p>\n\n\n\n<p>Read more, <a href=\"https:\/\/www.medpagetoday.com\/meetingcoverage\/asn\/95485?xid=nl_mpt_DHE_2021-11-06&amp;eun=g1917319d0r&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202021-11-06&amp;utm_term=NL_Daily_DHE_dual-gmail-definition\">here<\/a>.<\/p>\n<span class=\"simplefavorite-button has-count loading\" data-postid=\"3690\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>","protected":false},"excerpt":{"rendered":"<p>Loading &#8220;The investigational hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) daprodustat was safe and as effective as erythropoiesis-stimulating agents (ESAs) for anemia, according to the phase III ASCEND program. In the first &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2021\/11\/09\/investigational-oral-ckd-anemia-agent-effective-safe\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investigational Oral CKD-Anemia Agent Effective, Safe&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":3348,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":0,"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","_ecp_custom_2":"","footnotes":""},"categories":[912,2],"tags":[186,44],"post_format":[],"Dislikes":"","Likes":"","simplefavorites_count":"","views":"1645","post_likes_plusCounter":"1","post_dislikes_plusCounter":"","acf":[],"_links":{"self":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/3690"}],"collection":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/comments?post=3690"}],"version-history":[{"count":1,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/3690\/revisions"}],"predecessor-version":[{"id":3691,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/3690\/revisions\/3691"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media\/3348"}],"wp:attachment":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media?parent=3690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/categories?post=3690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/tags?post=3690"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/post_format?post=3690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}